|
Market Closed -
Nasdaq
16:30:00 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 3.142 USD | -4.19% |
|
-8.11% | -69.36% |
| 08-11 | Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-11 | Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 |
Company Valuation: Intensity Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 117.5 | 26.58 | 24.64 | 10.26 | - | - |
| Change | - | -77.37% | -7.32% | -58.36% | - | - |
| Enterprise Value (EV) | 117.5 | 26.58 | 24.64 | 10.26 | 10.26 | 10.26 |
| Change | - | -77.37% | -7.32% | -58.36% | 0% | 0% |
| P/E | -6.21x | -1.5x | -1.2x | -0.93x | -1.48x | -1x |
| PBR | - | - | - | - | - | - |
| PEG | 0.2x | 0.1x | 0x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | 0.29x |
| EV / Revenue | - | - | - | - | - | 0.29x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0.85x | -0.69x | -0.39x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -34.5 | -29.25 | -8.56 | -3.375 | -2.117 | -3.157 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 34.96 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -8.319 | -16.58 | -11.97 | -12.08 | -14.88 | -26.33 |
| Net income 1 | -11.86 | -16.27 | -11.61 | -11.79 | -14.93 | -27.41 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 214.250 | 44.000 | 10.255 | 3.142 | 3.142 | 3.142 |
| Nbr of stocks (in thousands) | 548 | 604 | 2,403 | 3,265 | - | - |
| Announcement Date | 3/14/24 | 3/13/25 | 3/27/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.97x | - | - | - | 10.71M | |
| 19.21x | 6.83x | 13.69x | 1.55% | 66.34B | |
| 36.32x | 6.47x | 19.31x | 0.89% | 52.92B | |
| 29.51x | 8.11x | 25.65x | 0.05% | 54.82B | |
| 34.13x | 3.33x | 14.37x | -.--% | 44.09B | |
| 50.62x | 5.85x | 32.15x | -.--% | 43.72B | |
| -20.41x | 209.35x | -21.69x | -.--% | 42.13B | |
| 29.48x | 8.35x | 21.6x | 0.36% | 33.96B | |
| 30.25x | 6.41x | 16.63x | -.--% | 26.17B | |
| 31.94x | 5.89x | 19.81x | -.--% | 23.37B | |
| Average | 24.01x | 28.95x | 15.73x | 0.32% | 38.75B | |
| Weighted average by Cap. | 26.35x | 28.52x | 15.73x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- INTS Stock
- Valuation Intensity Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
